Fred Schwarzer | Chief Executive Officer |
Misbah Tahir | Chief Financial Officer |
Chris Takimoto | Chief Medical Officer |
Mary Beth Harler | President-IGM Autoimmunity and Inflammation |
Bruce Keyt | Chief Scientific Officer |
Stephen Willey | Stifel |
Greg Harrison | Bank of America |
Michael Schmidt | Guggenheim |
Roger Song | Jefferies |
Joel Beatty | Baird |
Noah Eisenberg | JPMorgan |
Leonid Timashev | RBC Capital Markets |
Asthika Goonewardene | Truist |
Good day, everyone, and welcome to the IGM Biosciences’ Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Call. Today's call is being recorded.
At this time, I would like to turn the call over to Fred Schwarzer, Chief Executive Officer of IGM.
Thank you, operator. And thanks to all of you joining us on this call.